Literature DB >> 12044585

Postprandial lipemia--effect of lipid-lowering drugs.

Fredrik Karpe1.   

Abstract

Exaggerated postprandial hyperlipidemia has been associated with cardiovascular disease. The mechanisms underlying this association are likely to depend on a multitude of effects. Potentially atherogenic remnants of triglyceride-rich lipoproteins (TRL) accumulate in the postprandial state. In addition, TRL may promote the formation of small dense LDL. There are some indications that the postprandial period is a hypercoagulable state and endothelial function seems to be hampered after acute fat intake. Conventional lipid lowering drugs such as statins and fibrates have the potency of reducing postprandial hyperlipidemia, but the fibrates seem to be more effective in this respect. There is a complete lack of prospective studies linking inefficient postprandial lipid metabolism with clinical endpoints and there is also a need to include investigations of postprandial lipid metabolism in the evaluation of novel drugs affecting lipid metabolism and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044585     DOI: 10.1016/s1567-5688(01)00004-6

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  6 in total

1.  The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.

Authors:  G D Tan; B A Fielding; J M Currie; S M Humphreys; M Désage; K N Frayn; M Laville; H Vidal; F Karpe
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

2.  Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Authors:  Charlotte Koopal; A David Marais; Jan Westerink; Yolanda van der Graaf; Frank L J Visseren
Journal:  J Lipid Res       Date:  2017-09-19       Impact factor: 5.922

3.  Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.

Authors:  Limin Wang; Rajan Gill; Theresa L Pedersen; Laura J Higgins; John W Newman; John C Rutledge
Journal:  J Lipid Res       Date:  2008-09-23       Impact factor: 5.922

4.  Increased postprandial triglyceride-rich lipoprotein levels in elderly survivors of myocardial infarction.

Authors:  Samira Lekhal; Trond Børvik; Arne Nordøy; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-04-04       Impact factor: 1.880

5.  Extended-release niacin acutely suppresses postprandial triglyceridemia.

Authors:  M Haris U Usman; Arman Qamar; Ramprasad Gadi; Scott Lilly; Harsh Goel; Jaison Hampson; Megan L Mucksavage; Grace A Nathanson; Daniel J Rader; Richard L Dunbar
Journal:  Am J Med       Date:  2012-07-25       Impact factor: 4.965

6.  The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus.

Authors:  Faranak Sharifi; Nima Hojeghani; Saeideh Mazloomzadeh; Zahra Shajari
Journal:  J Diabetes Metab Disord       Date:  2013-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.